Table 1.
Data on study, population characteristics, and assessed outcomes included in the meta-analysis
| Author, year | Type of study | Intervention | Age (years)a | Number of patients | Total number of lesions | Functioning | Nonfunctioning | Female | Mean size (mm)a | Total number of sessions |
|---|---|---|---|---|---|---|---|---|---|---|
| Pai et al., 2015 | Prospective | RFA | 69.5±12.5 | 2 | 2 | 2 | 27.5±17.7 | 3 | ||
| Lakhtakia et al., 2016 | Prospective | RFA | 45±4.96 | 3 | 3 | 3 | 0 | 0 | 13±5.5 | 3 |
| Choi et al., 2018 | Prospective | RFA | 55±30.6 | 8 | 8 | 1 | 7 | 4 | 19.3±6.7 | 14 |
| De La Serna et al., 2018 | Prospective | RFA | 67.3±7.7 | 3 | 3 | NR | NR | 0 | 16.1±6.3 | 6 |
| Thosani et al., 2018 | Retrospective | RFA | NR | 3 | 3 | 3 | 0 | NR | 23 | 5 |
| Fathima et al., 2019 | Prospective | RFA | NR | 15 | 18 | 13 | 5 | NR | 13.6 | 17 |
| De Nucci et al., 2019 | Prospective | RFA | 78.6 | 10 | 11 | 3 | 8 | 4 | 14.5 (9-24) | 11 |
| Oleinikov et al., 2019 | Prospective | RFA | 60.4±14.4 | 18 | 25 | 8 | 19 | 8 | 14.3±7.3 | 18 |
| Dancour et al., 2019 | Prospective | RFA | 53.5±11.5 | 8 | 8 | 8 | 0 | 4 | 15.31±1.94 | 8 |
| Barthet et al., 2019 | Prospective | RFA | 59.9 (45-47) | 12 | 14 | 0 | 14 | 5 | 13.1 (10-20) | 14 |
| Trosic-Ivanisevic et al., 2019 | Retrospective | RFA | NR | 7 | 7 | 3 | 4 | NR | 11.8 (7.4-18) | 7 |
| Younis et al., 2019 | Prospective | RFA | 73.5 | 3 | 3 | 0 | 3 | NR | 10 (7-16) | 3 |
| Malikowski et al., 2020 | Prospective | RFA | 68.4±8.7 | 8 | 8 | 3 | 5 | 5 | 21.9±15.5 | 9 |
| Levy et al., 2012 | Prospective | Ethanol | 66.3±14.9 | 5 | 5 | 5 | 5 | 4 | 15±4.17 | 11 |
| Park et al., 2015 | Prospective | Ethanol | 52.5±20.5 | 11 | 14 | 4 | 4 | 6 | 12.3±3.2 | 18 |
| Yang et al., 2015 | Prospective | Ethanol | 59 | 4 | 4 | 4 | 4 | NR | N/A | 5 |
| Qin et al., 2016 | Prospective | Ethanol | 45.3±10.5 | 17 | 17 | 17 | 17 | 9 | 13.2±6.2 | 27 |
| Paik et al., 2016 | Prospective | Ethanol | 60±27 | 6 | 6 | 4 | 4 | 2 | 11.3±3.7 | 6 |
| Choi et al., 2018 | Prospective | Ethanol | 56.5±12.7 | 33 | 40 | 1 | 1 | 20 | 11 (range 7-20) | 63 |
| Matsumoto et al., 2020 | Prospective | Ethanol | 62.4±7.9 | 5 | 5 | 0 | 0 | 3 | 10.2±2.5 | 8 |
|
| ||||||||||
|
| ||||||||||
| Author, year | Location | Ethanol volume per session (mL)a, concentration (%) | Technical success | Clinical success | Total follow-up duration (months)a | Adverse events | Acute pancreatitis | Abdominal pain | Others | |
|
| ||||||||||
| Pai et al., 2015 | 2 head | NA | 3 | 2 | 3-6 | 0 | 0 | 0 | 0 | |
| Lakhtakia et al., 2016 | 2 head, 1 body | NA | 3 | 3 | 11-12 | 0 | 0 | 0 | 0 | |
| Choi et al., 2018 | 3 head, 5 body | NA | 14 | 6 | 13 | 2 | 1 | 1 | 0 | |
| De La Serna et al., 2018 | 1 head, 2 body | NA | 6 | 1 | 3-16 | 0 | 0 | 0 | 0 | |
| Thosani et al., 2018 | NR | NA | 5 | 3 | 5 | NR | NR | NR | NR | |
| Fathima et al., 2019 | NR | NA | 17 | 15 | 6-60 | 2 | 1 | 1 | 0 | |
| De Nucci et al., 2019 | 3 head, 6 body, 2 tail | NA | 11 | 11 | 12 | 0 | 0 | 0 | 0 | |
| Oleinikov et al., 2019 | 5 uncinate, 10 head, 8 body, 2 tail | NA | 18 | 25 | 2-27 | 0 | 2 | 0 | 0 | |
| Dancour et al., 2019 | 3 uncinate, 2 head, 2 body, 1 tail | NA | 8 | 8 | 1.5-21 | 0 | 0 | 0 | 0 | |
| Barthet et al., 2019 | 3 head, 6 body, 5 tail | NA | 14 | 12 | 12 | 2 | 1 | 1 | 0 | |
| Trosic-Ivanisevic et al., 2019 | 2 uncinate, 3 neck, 2 body | NA | 7 | 6 | 43876 | 4 | 0 | 3 | 1 (pancreatic fistula) | |
| Younis et al., 2019 | NR | NA | 3 | 1 | 0 | 1 | 0 | |||
| Malikowski et al., 2020 | 6 head, 1 neck, 1 body | NA | 9 | 8 | 1 | 1 | 0 | 0 | 0 | |
| Levy et al., 2012 | 3 head, 1 body, 1 tail | 1.2±1.7, 95%-98% | 11 | 4 | 17.3±11.5 | 0 | 0 | 0 | 0 | |
| Park et al., 2015 | 1 uncinate, 6 head, 7 body/tail | median 1.6 (range, 0.5-3.8), 99% | 18 | 92 | 14.8±8.1 | 5 | 3 | 2 | 0 | |
| Yang et al., 2015 | NR | 3.1, 98% | 5 | 3 | 17.3 | 0 | 0 | 0 | 0 | |
| Qin et al., 2016 | 5 head, 2 neck, 4 body, 6 tail | Mean 1.0 (range, 0.4-1.05 mL), NR | 27 | 17 | 1-21 | 0 | 0 | 0 | 0 | |
| Paik et al., 2016 | 4 head, 2 body | 2.4±1.4, 99% | 6 | 5 | 16.5 (range, 5.4-55.3) | 3 | 1 | 1 | 1 Fever | |
| Choi et al., 2018 | 23 uncinate/head, 17 body/tail | 1.1 (0.8-1.9), 99% | 63 | 24 | 42 (median 39-46) | 2 | 2 | 0 | 0 | |
| Matsumoto et al., 2020 | 2 head, 1 body, 2 tail | 0.7±0.2, 100% | 8 | 4 | 12 | 0 | 0 | 0 | 0 | |
a Values are reported as mean±SD or median (range) or range; b1 patient lost to follow-up. RFA: Radiofrequency ablation; NR: Not reported; NA: Not applicable; SD: Standard deviation